RT Journal Article
T1 Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain
T2 Análisis de minimización de costes del tratamiento de acción prolongada con palmitato de paliperidona frente al tratamiento de acción prolongada con risperidona para la esquizofrenia en España
A1 Quintero Gutiérrez Del Álamo, Francisco Javier
A1 Oyagüez, Itziar
A1 González, Beatriz
A1 Cuervo-Arango, Ignacio
A1 García Cabeza, Ignacio
A1 Casado, Miguel Ángel
AB Background and objective: Long-acting formulations for paliperidone (PPLAT) and risperidone (RLAT) are effective second-generation antipsychotics. This study aimed to compare treatment costs between PPLAT and RLAT in schizophrenia patients.Methods: A cost-minimization analysis was performed from the perspective of the Spanish National Healthcare System (NHS), in line with the approach accepted by the Scottish Medicine Consortium evaluation. Only direct health costs (€, 2015) were included, i.e. medication (including oral antipsychotic drug supplementation), hospitalization and cost of administration in the community. Two time horizons were used: 1 year (to compare initiation treatment) and 2 years (to compare maintenance treatment). Base-case considered the following assumptions: setting for treatment initiation (50 % hospital and 50 % community); 50 % of patients initiating from a long-acting treatment and 50 % from an oral antipsychotic; no reduction in the length of stay. One-way sensitivity analyses (SA) were performed.Results: The estimated costs/patient were €7698 (PPLAT) and €8168 (RLAT) for the first year, and €4314 (PPLAT) and €5003 (RLAT) for the second year. Cost savings related to PPLAT therapy were €470 and €689 for first and second year, respectively. SA results confirmed the robustness of the model results, even in the most conservative scenarios: (1) if 100 % of patients initiate treatment in hospital, the savings could be €454 per patient; (2) if 100 % of patients initiate treatment from an oral antipsychotic, the savings could be €277 per patient/year; and (3) if PPLAT could not reduce the length of stay by approximately one-third, as some studies indicate, the savings could be €470 per patient/year.Conclusions: The use of PPLAT instead of RLAT could be a cost-saving strategy for the Spanish NHS.
PB Springer
SN 1179-1918
YR 2015
FD 2015
LK https://hdl.handle.net/20.500.14352/96937
UL https://hdl.handle.net/20.500.14352/96937
LA eng
NO Quintero, J., Oyagüez, I., González, B. et al. Cost-Minimisation Analysis of Paliperidone Palmitate Long-Acting Treatment versus Risperidone Long-Acting Treatment for Schizophrenia in Spain. Clin Drug Investig 36, 479–490 (2016). https://doi.org/10.1007/s40261-016-0393-z
NO Johnson & Johnson Innovative Medicine
DS Docta Complutense
RD 19 abr 2025